TUS

Aptose Reports Results for the Fourth Quarter and Full Year 2023

Retrieved on: 
Tuesday, March 26, 2024
Indian stock exchange, Absorption, Plasma, Exercise, Hanmi Pharmaceutical, AML, BID, Patient, APS, SAN, Venetoclax, G1, VEN, FLT3, EHA, LUX, Acute myeloid leukemia, Trial of the century, TUS, TSX, Hanmi, Azacitidine, G3, Pharmaceutical industry

This included 736,842 Common Shares and warrants pursuant to a full exercise by the underwriter of its over-allotment option.

Key Points: 
  • This included 736,842 Common Shares and warrants pursuant to a full exercise by the underwriter of its over-allotment option.
  • Total gross proceeds from the public offering were approximately $9.7 million before deducting underwriting costs, placement agent commissions and other offering-related expenses.
  • Private Placement – On January 31, 2024, Aptose closed a US $4 million private placement of common shares with strategic partner Hanmi Pharmaceutical.
  • Luxeptinib G3 Evaluation Completed – During 2023 and early 2024, clinical evaluation of the new generation 3 (G3) formulation of luxeptinib (LUX) was completed.

PLANTERS® Brand Team Introduces New Flavor-Forward Innovation in Snack Nuts with Launch of PLANTERS® Nut Duos Snacks

Retrieved on: 
Tuesday, April 2, 2024
Taste, Coffee, Parmesan, Magic, Cheese, Seed, TUS, Nut, Snack, Chocolate, Convenience food

AUSTIN, Minn., April 2, 2024 /PRNewswire/ -- When you think of dynamic duos, a few foodie examples come to mind. There's peanut butter and jelly, classic spaghetti and meatballs, and of course, macaroni and cheese. Now the makers of the PLANTERS® brand, the No. 1 selling snack nuts brand,* are adding to that legendary list with their latest crunch-time innovation: the all-new PLANTERS® Nut Duos snacks, now available from retailers nationwide.

Key Points: 
  • AUSTIN, Minn., April 2, 2024 /PRNewswire/ -- When you think of dynamic duos, a few foodie examples come to mind.
  • 1 selling snack nuts brand,* are adding to that legendary list with their latest crunch-time innovation: the all-new PLANTERS® Nut Duos snacks, now available from retailers nationwide.
  • "The combination of flavors and textures with our new PLANTERS® Nut Duos snacks is magic," said Ashley Krautkramer-Gonya, senior brand manager for the PLANTERS® brand.
  • "The combination of nut types and flavors is what makes PLANTERS® Nut Duos snacks truly unique to our consumers," Krautkramer-Gonya said.

Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

Retrieved on: 
Saturday, December 9, 2023
VEN, NPM1, Aes, TUS, SYK, KIT, MD Anderson Cancer Center, Society, Infrared spectroscopy correlation table, CRC, ASH, Toxicity, TSX, Patient, Acute myeloid leukemia, Safety, University, AML, Pharmaceutical industry

Data were presented in an oral presentation today at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition by lead investigator Naval G. Daver, M.D., Professor, Director Leukemia Research Alliance Program, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

Key Points: 
  • Data were presented in an oral presentation today at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition by lead investigator Naval G. Daver, M.D., Professor, Director Leukemia Research Alliance Program, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Tuspetinib is a once-daily, oral, precision targeted kinase inhibitor that suppresses select kinases that drive the proliferation of AML.
  • Dr. Daver reported data from more than 100 relapsed/refractory patients from multiple international clinical sites, who had failed prior therapy and then were treated with tuspetinib (TUS) as a single agent or tuspetinib in combination with venetoclax (TUS/VEN).
  • We look forward to reporting our next set of data in the first quarter of 2024.”

Aptose Reports Results for the Third Quarter 2023

Retrieved on: 
Thursday, November 9, 2023
Apoptosis, ASH, University, Acute myeloid leukemia, APS, Patient, Poster, VEN, SYK, TUS, FLT3, ORR, KIT, CMML, Toxic leukoencephalopathy, AML, MD Anderson Cancer Center, Society, TSX, Cell, European School, Pharmaceutical industry, Airline, Venetoclax

“Investigator enthusiasm for our tuspetinib/venetoclax (TUS/VEN) doublet has led to brisk enrollment in the APTIVATE trial.

Key Points: 
  • “Investigator enthusiasm for our tuspetinib/venetoclax (TUS/VEN) doublet has led to brisk enrollment in the APTIVATE trial.
  • In the most recent data cut (October 23, 2023), the favorable safety profile remained consistent for TUS and TUS/VEN treated R/R AML patients.
  • Aptose researchers investigated the effects of TUS on key elements of the phospho-kinome and apoptotic proteome in both parental and TUS-resistant AML cells.
  • APTIVATE oral presentation at ASH 2023 by Dr.

Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

Retrieved on: 
Monday, October 30, 2023
APS, VEN, TUS, KIT, Acute myeloid leukemia, SYK, European School, Treatment, MD, Conference, Doctor of Philosophy, ORR, University, FLT3, Safety, International Conference on Population and Development, MD Anderson Cancer Center, Patient, TSX, AML, Response-rate ratio, SAN, Toxic leukoencephalopathy, Pharmaceutical industry, Airline, Biology

Dr. Daver is the lead investigator on Aptose’s APTIVATE trial of tuspetinib and is recognized for significant achievements in the development of novel acute myeloid leukemia (AML) treatments, including several combination therapies.

Key Points: 
  • Dr. Daver is the lead investigator on Aptose’s APTIVATE trial of tuspetinib and is recognized for significant achievements in the development of novel acute myeloid leukemia (AML) treatments, including several combination therapies.
  • Tuspetinib (TUS) is a once-daily, oral, precision targeted kinase inhibitor that suppresses select kinases that drive the proliferation of AML.
  • “We are really pleased by our growing safety and efficacy data on tuspetinib in very difficult-to-treat AML patient populations,” said Dr. Bejar.
  • “Data from the TUS/VEN doublet gives us confidence to move tuspetinib forward into a TUS/VEN/HMA triplet for the treatment of frontline newly-diagnosed AML patients.

Granite Continues Airfield Safety Enhancement Program at Tucson International Airport

Retrieved on: 
Thursday, November 2, 2023
Other Transport, Air, Transport, Commercial Building & Real Estate, Construction & Property, TUS, NYSE, Tucson International Airport, General aviation, Federal Aviation Administration, GVA, TAA, GMP, Safety, Airport Improvement Program, Airport, Sand, FAA, Airline, Risk

Granite (NYSE:GVA) announced today that it has been awarded an approximately $12 million dollar contract by the Tucson Airport Authority (TAA) as part of the TAA’s estimated $400 million, multi-year Airfield Safety Enhancement Program at Tucson International Airport (TUS).

Key Points: 
  • Granite (NYSE:GVA) announced today that it has been awarded an approximately $12 million dollar contract by the Tucson Airport Authority (TAA) as part of the TAA’s estimated $400 million, multi-year Airfield Safety Enhancement Program at Tucson International Airport (TUS).
  • The majority of funding will come from the Federal Aviation Administration (FAA) through the Airport Improvement Program, and the TAA will provide the requisite matching share.
  • “Granite has been working consistently at Tucson International Airport for the past 10+ years and has built a solid reputation for its work product.
  • We are the go-to contractor for airside civil work in a secure environment,” said Zach Thompson, Granite Area Manager.

Vibrato Medical Announces Positive Results for Early Feasibility Study of Wearable, Non-Invasive Therapeutic Ultrasound to Treat Chronic Limb-Threatening Ischemia (CLTI)

Retrieved on: 
Wednesday, November 1, 2023
Health, Medical Devices, Radiology, Clinical Trials, Research, Science, Cardiology, Blood vessel, TUS, Patient, Heart, Chronic limb threatening ischemia, Medicine, Vasodilation, CLTI, Perfusion, Vibrato, Ischemia, Claudication, Moyamoya disease, Disease, Orange County, VIVA, Amputation, PAD, Perception, Wynn Las Vegas, Prelude, Medical imaging, Pharmaceutical industry, MD

Vibrato Medical, an innovator in the treatment of peripheral arterial disease (PAD), announced today that data from an early feasibility study of Non-Invasive Therapeutic Ultrasound (TUS) to treat Chronic Limb-Threatening Ischemia (CLTI) has successfully met its endpoint.

Key Points: 
  • Vibrato Medical, an innovator in the treatment of peripheral arterial disease (PAD), announced today that data from an early feasibility study of Non-Invasive Therapeutic Ultrasound (TUS) to treat Chronic Limb-Threatening Ischemia (CLTI) has successfully met its endpoint.
  • The study evaluated patients with infrapopliteal PAD and measured changes in foot perfusion and oxygenation as well as therapy tolerance, compliance and perception.
  • Patients in the trial had Rutherford class 3, 4 or 5 PAD, meaning severe claudication, ischemic rest pain or tissue loss including nonhealing ulcers.
  • “These early findings are promising for the future of non-invasive therapeutic options to treat chronic limb-threatening ischemia,” said Juliana Elstad, CEO at Vibrato.

First Round of Late-Breaking Clinical Trial Results Announced at VIVA23

Retrieved on: 
Tuesday, October 31, 2023
Atheroma, Peripheral artery disease, Diabetes, Pivotal trial, Ulcer, Transducer, Male, Disease, PAP, Buerger's test, Classification, The Unreconstructed M, IVUS, Amputation, Stent, PAD, PP, Thorpe tube flowmeter, TUS, Calf, Chin Na, Vein, Telephone, TASC, Bare, Vibrato, Life, SP, W. L. Gore & Associates, VIVA, Safety, Patient, Dyslipidemia, Blood vessel, Plaque, History, CLTI, Coronary artery disease, Perfusion, Restenosis, Research, Foot, Spur, Atherectomy, Șaeș, Artery, Education, DCB, Doppler effect, Dialysis, Hypertension, FP, Freedom, Wynn Las Vegas, Wound healing, Medical imaging, Pharmaceutical industry, Birth control, Surveying, Medtronic

Below are highlights of this morning's 5 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this morning's 5 late-breaking clinical trial presentations.
  • At 20 centers without roll-ins across the United States, 105 no-option CLTI patients were enrolled in a nonrandomized manner.
  • The median age was 70 years, two-thirds of the patients were male, and one-quarter of patients were Hispanic or Latino.
  • 1-Year Results of the DEEPER OUS Trial: The Bare Temporary Spur Stent System in Combination With a Paclitaxel-Coated Balloon
    The DEEPER OUS trial is a prospective, nonrandomized, multicenter, single-arm trial taking place in New Zealand, Germany, and Switzerland.

Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th

Retrieved on: 
Monday, October 23, 2023
VEN, TUS, Acute myeloid leukemia, European School, Treatment, MD, Conference, Abstract, SAN, Venetoclax, University, FLT3, Safety, MD Anderson Cancer Center, Patient, TSX, AML, International Conference on Learning Representations, Pharmaceutical industry, Biology

Dr. Daver is the lead investigator on Aptose’s APTIVATE trial and is recognized for significant achievements in the development of novel AML treatments, including several combination therapies.

Key Points: 
  • Dr. Daver is the lead investigator on Aptose’s APTIVATE trial and is recognized for significant achievements in the development of novel AML treatments, including several combination therapies.
  • Tuspetinib also is being studied in combination with venetoclax (VEN) in the APTIVATE international Phase 1/2 expansion trial in R/R AML patients.
  • Notably, tuspetinib targets venetoclax resistance mechanisms that may re-sensitize Prior-VEN failure patients to venetoclax.
  • Note that the poster presentations will include additional data not found in the abstracts.

Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference

Retrieved on: 
Monday, October 16, 2023
TSX, Abstract, TUS, International Conference on Emerging Infectious Diseases, Treatment, Trial of the century, Apoptosis, European School, AML, VEN, RSK, Acute myeloid leukemia, SAN, SYK, KIT, FLT3, Conference, Patient, Pharmaceutical industry, Biology

Aptose is planning to hold a clinical update webcast on October 30, 2023, to provide additional up-to-date data on tuspetinib.

Key Points: 
  • Aptose is planning to hold a clinical update webcast on October 30, 2023, to provide additional up-to-date data on tuspetinib.
  • The posters accepted for presentation are listed below and can be viewed beginning October 29, 2023, on site at the ESH poster exhibit hall and online on the Aptose website here .
  • Notably, TUS targets VEN resistance mechanisms and appears to re-sensitize Prior-VEN failure patients to VEN.
  • We investigated the effects of TUS on key elements of the phosphokinome and apoptotic proteome in both parental and TUS-resistant AML cells.